Polymorphism of tumor necrosis factor–α and interleukin-10 gene promoter region in chronic hepatitis C virus patients and their effect on pegylated interferon–α therapy response

Dogra, G. S.; Chakravarti, Anita; Kar, Premashish; Chawla, Yogesh

doi:10.1016/j.humimm.2011.06.008

Cited by 34 publications

(27 citation statements)

References 30 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, 62.1% of the A allele were found in late fibrosis patients (F2-F4) compared to 37.9% in early fibrosis patients (F0-F1) ( P = 0.015). Similar results were found by Dogra et al[29], who reported that the frequency of TNFα -308 genotypes was significantly different between healthy controls and HCV patients. The association between TNFα -308A allele and HCV persistence and failure of response to IFN treatment was reported by Radwan et al[30] and Dai et al[31].…”

Section: Discussionsupporting

confidence: 91%

Tumor necrosis factor-α -G308A polymorphism is associated with liver pathological changes in hepatitis C virus patients

Din

Farouk

El‐Shenawy

et al. 2016

WJG

View full text Add to dashboard Cite

AIMTo investigate the association of tumor necrosis factor alpha (TNFα) -G308A polymorphism with different liver pathological changes in treatment-naïve Egyptian patients infected with hepatitis C virus (HCV) genotype 4.METHODSThis study included 180 subjects, composed of 120 treatment-naïve chronic HCV patients with different fibrosis grades (F0-F4) and 60 healthy controls. The TNFα -G308A region was amplified by PCR and the different genotypes were detected by restriction fragment length polymorphism analysis. The TNFα protein was detected by enzyme-linked immunosorbent assay. The influence of different TNFα -G308A genotypes on TNFα expression and liver disease progression were statistically analyzed. The OR and 95%CI were calculated to assess the relative risk confidence.RESULTSCurrent data showed that the TNFα -G308A SNP frequency was significantly different between controls and HCV infected patients (P = 0.001). Both the AA genotype and A allele were significantly higher in late fibrosis patients (F2-F4, n = 60) than in early fibrosis patients (F0-F1, n = 60) (P = 0.05, 0.04 respectively). Moreover, the GA or AA genotypes increased the TNFα serum level greater than the GG genotype (P = 0.002). The results showed a clear association between severe liver pathological conditions (inflammation, steatosis and fibrosis) and (GA + AA) genotypes (P = 0.035, 0.03, 0.04 respectively). The stepwise logistic regression analysis showed that the TNFα genotypes (GA + AA) were significantly associated with liver inflammation (OR = 3.776, 95%CI: 1.399-10.194, P = 0.009), severe steatosis (OR = 4.49, 95%CI: 1.441-14.0, P = 0.010) and fibrosis progression (OR = 2.84, 95%CI: 1.080-7.472, P = 0.034). Also, the A allele was an independent risk factor for liver inflammation (P = 0.003), steatosis (P = 0.003) and fibrosis (P = 0.014).CONCLUSIONTNFα SNP at nucleotide -308 represents an important genetic marker that can be used for the prognosis of different liver pathological changes in HCV infected patients

show abstract

Section: Discussionsupporting

confidence: 91%

Tumor necrosis factor-α -G308A polymorphism is associated with liver pathological changes in hepatitis C virus patients

Din

Farouk

El‐Shenawy

et al. 2016

WJG

View full text Add to dashboard Cite

show abstract

“…A polymorphism near the IL28B gene encoding IFN lambda 3 is associated with depressive symptoms, including subjective appetite, energy, and sleep complaints (Lotrich et al, 2010). In addition to IL28B , the risk for developing adverse neuropsychiatric symptoms during or following methamphetamine abuse may be influenced by genetic polymorphisms in other cytokine genes, including IL-6 ( IL6 ) (Bull et al, 2009), tumor necrosis factor-alpha ( TNF ) (Dogra, Chakravarti, Kar, & Chawla, 2011; Thio et al, 2004), and interferon-γ ( IFNG ) (Oxenkrug et al, 2011)—genetic variations which may have implications for the management and treatment of methamphetamine dependence and other substance use disorders (with or without comorbid viral infection).…”

Section: Partmentioning

confidence: 99%

Neuroimmune Basis of Methamphetamine Toxicity

Loftis

Janowsky

2014

International Review of Neurobiology

105

View full text Add to dashboard Cite

Although it is not known which antigen-specific immune responses (or if antigen-specific immune responses) are relevant or required for methamphetamine's neurotoxic effects, it is apparent that methamphetamine exposure is associated with significant effects on adaptive and innate immunity. Alterations in lymphocyte activity and number, changes in cytokine signaling, impairments in phagocytic functions, and glial activation and gliosis have all been reported. These drug-induced changes in immune response, particularly within the CNS, are now thought to play a critical role in the addiction process for methamphetamine dependence as well as for other substance use disorders. In Section 2, methamphetamine's effects on glial cell (e.g., microglia and astrocytes) activity and inflammatory signaling cascades are summarized, including how alterations in immune cell function can induce the neurotoxic and addictive effects of methamphetamine. Section 2 also describes neurotransmitter involvement in the modulation of methamphetamine's inflammatory effects. Section 3 discusses the very recent use of pharmacological and genetic animal models which have helped elucidate the behavioral effects of methamphetamine's neurotoxic effects and the role of the immune system. Section 4 is focused on the effects of methamphetamine on blood–brain barrier integrity and associated immune consequences. Clinical considerations such as the combined effects of methamphetamine and HIV and/or HCV on brain structure and function are included in Section 4. Finally, in Section 5, immune-based treatment strategies are reviewed, with a focus on vaccine development, neuroimmune therapies, and other anti-inflammatory approaches.

show abstract

“…The most effective standard treatment in patients with chronic hepatitis C is a combination of pegylated interferon with ribavirin (18). The exact mechanisms by which interferon therapy alters the course of HCV disease have not been fully described.…”

Section: Introductionmentioning

confidence: 99%

Serum Profile of T Helper 1 and T Helper 2 Cytokines in Hepatitis C Virus Infected Patients

et al. 2012

View full text Add to dashboard Cite

BackgroundT-helper (Th) lymphocyte cytokine production may be important in the immune pathogenesis of hepatitis C virus (HCV) infections. Th1 cytokines such as; interleukin-2 (IL-2), and interferon gamma (IFN-gamma) are necessary for host antiviral immune responses, while Th2 cytokines (IL-4, IL-10) can inhibit the development of these effector mechanisms.ObjectivesThe aim of the present study was to assess the serum profile of Th1 and Th2 cytokines in treated and non-treated HCV infected individuals.Patients and MethodsThis study was carried out in 63 HCV infected patients (31 under treatment and 32 untreated) and 32 matched HCV-sero negative healthy subjects. Serum samples were checked with an enzyme-linked immune sorbent assay (ELISA) for IL-2, IL-4, IL-10 and IFN-gamma.ResultsLevels of circulating IL-2, IL-4, IL-10 and IFN-gamma were significantly elevated in HCV patients versus normal controls (2 822.6 ± 1 259.92 vs. 950.8 ± 286.9 pg/mL; 1 987 ± 900.69 vs. 895.91 ± 332.33 pg/mL; 1 688.5 ± 1 405.1 vs. 519.03 ± 177.64 pg/mL and 1 501.9 ± 1 298 vs. 264.66 ± 71.59 pg/mL, respectively; P < 0.001). The serum levels of all cytokines were significantly lower in the patients under treatment than those of the untreated patients (P < 0.001).ConclusionsOn the basis of our data, the simultaneous increase of Th1 and Th2 related cytokines may indicate that both Thl and Th2 cytokines are involved in the pathogenesis of HCV infections. Moreover, this activated T-cell response in HCV infected patients may be regulated by treatment.

show abstract

Polymorphism of tumor necrosis factor–α and interleukin-10 gene promoter region in chronic hepatitis C virus patients and their effect on pegylated interferon–α therapy response

Cited by 34 publications

References 30 publications

Tumor necrosis factor-α -G308A polymorphism is associated with liver pathological changes in hepatitis C virus patients

Tumor necrosis factor-α -G308A polymorphism is associated with liver pathological changes in hepatitis C virus patients

Neuroimmune Basis of Methamphetamine Toxicity

Serum Profile of T Helper 1 and T Helper 2 Cytokines in Hepatitis C Virus Infected Patients

Contact Info

Product

Resources

About